Edgar Filing: Cardium Therapeutics, Inc. - Form 4

Cardium Therapeutics, Inc. Form 4 August 11, 2008								
FORM 4 UNITED						PPROVAL		
UNITED		RITIES AN ashington, I		NGE COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Section 17(a) of the Public Utility Holding Company Act of 1934, Section 17(a) of the Investment Company Act of 1940 Section 17(a) of the Investment Company Act of 1940								
1(b). (Print or Type Responses)								
1. Name and Address of Reporting Moreadith Randall		Ficker or Tradir	Issuer XMI	of Reporting Person(s) to				
	(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 1 VALLEY CENTER DRIVE, 08/05/2008			(Chec Director Officer (give below)	Officer (give titleX Other (specify			
(Street)		nendment, Date onth/Day/Year)	e Original	Applicable Line) _X_ Form filed by (6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
SAN DIEGO, CA 92130				Person	note than One K	eporting		
(City) (State)	(Zip) Tal	ble I - Non-De	rivative Secur	ities Acquired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		3.4.TransactionACodeD	Acquired (A) or Disposed of (D) Instr. 3, 4 and 5 (A) or	5. Amount of Securities H Beneficially () Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect		
Reminder: Report on a separate line	e for each class of sec	curities benefici	-	ectly or indirectly.	tion of S	SEC 1474		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amou
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Secur
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am Nui Sha
Incentive Stock Option (right to buy)	\$ 2.75	08/05/2008		J <u>(1)</u>	46,838	(2)	11/05/2008	Common Stock	72
Non-Qualified Stock Option (right to buy)	\$ 2.75	08/05/2008		J <u>(1)</u>	140,692	(2)	11/05/2008	Common Stock	23

Edgar Filing: Cardium Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Moreadith Randall 3611 VALLEY CENTER DRIVE, SUITE 525 SAN DIEGO, CA 92130				Former Exec. VP and CMO		
Signatures						
/s/ Tyler Dylan on behalf of Dr. Moreadith under a Power of Attorney			0	8/08/2008		
**Signature of Reporting Person				Date		
Evalenction of Decremence.						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This does not represent a new stock option grant. Dr. Moreadith's employment with Cardium ended on August 5, 2008. This transaction represents the cancellation of unvested stock options as of August 5, 2008 and a change in the expiration date from January 16, 2016 to November 5, 2008 for the remaining vested options as a result of the end of his employment in accordance with the terms of the

- underlying stock option agreement.
- (2) The options vested 25%, in the aggregate, on January 17, 2007, and 2.083% per month, in the aggregate, thereafter until August 5, 2008.
- (3) These options were cancelled upon cessation of Dr. Moreadith's employment. Therefore, there is no price to report.

Remarks:

Dr. Moreadith's employment with Cardium Therapeutics, Inc. ended on August 5, 2008 and he ceased being an officer as of su

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.